AstraZeneca’s IMED to integrate Emulate’s Organ-Chip technology into everyday operations

Science

AstraZeneca has embedded Emulate’s Organ-Chip technology into its own research team. The chips are about the size of an AA battery and contain tiny hollow channels lined with living human cells and tissues. To begin with, the Liver-Chip will be used for safety testing across the Astrazeneca pipeline producing Organ-Chip data within the regulatory framework for new drugs.

Dr. Mene Pangalos, Executive Vice-President of AstraZeneca’s IMED Biotech Unit and Global Business Development said: “Organs-on-Chips technology has the potential to enhance and accelerate our ability to translate science into innovative medicines for patients. Working side by side with Emulate scientists will enable us to better develop the platform and may improve our ability to predict adverse and non-adverse effects in humans."

“AstraZeneca has embedded Emulate’s Organ-Chip technology into its own research team. The chips are about the size of an AA battery and contain tiny hollow channels lined with living human cells and tissues.“

This technology will enable animal testing to be scaled back as it will replicate the environment of a human organ more accurately than an animal model. It will also reduce time and R&D costs. Emulate are also working with Takeda, Roche, Merck and Janssen, and hope to shed new light on human disease mechanisms and allow researchers to predict the clinical relevance of candidate drug safety and efficiency.

See all the latest jobs in Science
Return to news